NEW MARKERS FOR DIAGNOSIS AND PROGNOSIS OF COGNITIVE IMPAIRMENT IN PATIENTS WITH MULTIPLE SCLEROSIS (review)
PDF

Keywords

multiple sclerosis, cognitive impairment, brain neurotrophic factor (BDNF), neurodegeneration, neuroimaging

How to Cite

Teslenko, O., & Tovazhnyanska, O. (2022). NEW MARKERS FOR DIAGNOSIS AND PROGNOSIS OF COGNITIVE IMPAIRMENT IN PATIENTS WITH MULTIPLE SCLEROSIS (review). Inter Collegas, 9(1), 14-18. https://doi.org/10.35339/ic.9.1.14-18

Abstract

The article presents modern approaches about the diagnosis of brain damage and the development of cognitive impairment in patients with multiple sclerosis. Neurodegenerative changes are considered, which take place in the early stages of the disease and play an important role in the formation of irreversible neurological deficits. Cognitive impairment in patients with multiple sclerosis is quite common, but they are not always noticed, but they significantly reduce patients' quality of life. The article describes the possibilities of neuroimaging methods to identify structural changes in the parts of the brain responsible for cognitive functions. The importance of brain neurotrophic factor (BDNF) as a promising biomarker of multiple sclerosis is presented. Further study of BDNF remains interesting, which will allow to develop algorithms for early diagnosis and prediction of disease progression, that will provide an opportunity to deepen the understanding of the place of BDNF in the pathomorphological chain of nervous system damage in multiple sclerosis.

https://doi.org/10.35339/ic.9.1.14-18
PDF

References

Shmidt, T.E. (2014). Multiple sclerosis: epidemiology, risk factors, pathogenesis, clinical features and progres-sion (according to the materials of the 29th Congress of ECTRIMS). Neurological J., 19(1), 49‒54.

Compston, A., & Coles, A. (2008). Multiple sclerosis. Lancet, 372, 1502‒1517.

Fernández-Muñoz, J. J., Morón-Verdasco, A., Cigarán-Méndez, M., Muñoz-Hellín, E., Pérez-de-Heredia-Torres, M., & Fernández-de-las-Peñas, C. (2015). Disability, quality of life, personality, cognitive and psychological variables associated with fatigue in patients with multiple sclerosis. Acta neurologica Scandinavica, 132(2), 118–124. https://doi.org/10.1111/ane.12370

Eijlers, A., van Geest, Q., Dekker, I., Steenwijk, M. D., Meijer, K. A., Hulst, H. E., … & Geurts, J. (2018). Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain: a journal of neurology, 141(9), 2605–2618. https://doi.org/10.1093/brain/awy202

Robinson, R. C., Radziejewski, C., Spraggon, G., Greenwald, J., Kostura, M. R., Burtnick, L. D., Stuart, D. I., Choe, S., & Jones, E. Y. (1999). The structures of the neurotrophin 4 homodimer and the brain-derived neu-rotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site. Protein science: a publication of the Protein Society, 8(12), 2589–2597. https://doi.org/10.1110/ps.8.12.2589

Siegert., R, & Abernethy, D. (2005). Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry, 76, 469–475.

Arnett., P., Barwick, F., & Beeney, J. (2008). Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc, 14, 691–724.

Sumowski, J. F., Benedict, R., Enzinger, C., Filippi, M., Geurts, J. J., Hamalainen, P., … & Rao, S. (2018). Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology, 90(6), 278–288. https://doi.org/10.1212/WNL.0000000000004977

Migliore, S., Ghazaryan, A., Simonelli, I., Pasqualetti, P., Squitieri, F., Curcio, G., Landi, D., Palmieri, M. G., Moffa, F., Filippi, M. M., & Vernieri, F. (2017). Cognitive Impairment in Relapsing-Remitting Multiple Sclero-sis Patients with Very Mild Clinical Disability. Behavioural neurology, 2017, 7404289. https://doi.org/10.1155/2017/7404289

Lovera, J., & Kovner, B. (2012). Cognitive impairment in multiple sclerosis. Current neurology and neurosci-ence reports, 12(5), 618–627. https://doi.org/10.1007/s11910-012-0294-3

Schulz, D., Kopp, B., Kunkel, A., & Faiss, J. H. (2006). Cognition in the early stage of multiple sclerosis. Journal of neurology, 253(8), 1002–1010. https://doi.org/10.1007/s00415-006-0145-8

Langdon D. W. (2011). Cognition in multiple sclerosis. Current opinion in neurology, 24(3), 244–249. https://doi.org/10.1097/WCO.0b013e328346a43b

Lezak, M. D., Howieson, D. B., Bigler, E. D., & Tranel, D. (2012). Neuropsychological Assessment. 5th ed. New York: Oxford University Press. 1576 p.

Hankomäki, E., Multanen, J., Kinnunen, E., & Hämäläinen, P. (2014). The progress of cognitive decline in newly diagnosed MS patients. Acta neurologica Scandinavica, 129(3), 184–191. https://doi.org/10.1111/ane.12161

Amato, M. P., Ponziani, G., Siracusa, G., & Sorbi, S. (2001). Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Archives of neurology, 58(10), 1602–1606. https://doi.org/10.1001/archneur.58.10.1602

Giazkoulidou, A., Messinis, L., & Nasios, G. (2019). Cognitive functions and social cognition in multiple sclerosis: An overview. Hellenic journal of nuclear medicine, 22 Suppl, 102–110. PMID: 30877728.

Trenova, A. G., Slavov, G. S., Manova, M. G., Aksentieva, J. B., Miteva, L. D., & Stanilova, S. A. (2016). Cognitive Impairment in Multiple Sclerosis. Folia medica, 58(3), 157–163. https://doi.org/10.1515/folmed-2016-0029

Achiron, A., Chapman, J., Magalashvili, D., Dolev, M., Lavie, M., Bercovich, E., … & Barak, Y. (2013). Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PloS one, 8(8), e71058. https://doi.org/10.1371/journal.pone.0071058

Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., … & Attendees of the Correlation between Pathological MRI findings in MS workshop (2012). Association between pathological and MRI findings in multiple sclerosis. The Lancet. Neurology, 11(4), 349–360. https://doi.org/10.1016/S1474-4422(12)70003-0

Assouad, R., Louapre, C., Tourbah, A., Papeix, C., Galanaud, D., Lubetzki, C., & Stankoff, B. (2014). Clini-cal and MRI characterization of MS patients with a pure and severe cognitive onset. Clinical neurology and neurosur-gery, 126, 55–63. https://doi.org/10.1016/j.clineuro.2014.08.018

Codella, M., Rocca, M. A., Colombo, B., Rossi, P., Comi, G., & Filippi, M. (2002). A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. Journal of neurology, 249(5), 535–537. https://doi.org/10.1007/s004150200060

Comini-Frota, E. R., Rodrigues, D. H., Miranda, E. C., Brum, D. G., Kaimen-Maciel, D. R., Donadi, E. A., & Teixeira, A. L. (2012). Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI le-sions in multiple sclerosis. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 45(1), 68–71. https://doi.org/10.1590/s0100-879x2011007500165

Frota, E. R., Rodrigues, D. H., Donadi, E. A., Brum, D. G., Maciel, D. R., & Teixeira, A. L. (2009). In-creased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neuroscience letters, 460(2), 130–132. https://doi.org/10.1016/j.neulet.2009.05.057

Lewin, G. R., & Barde, Y. A. (1996). Physiology of the neurotrophins. Annual review of neuroscience, 19, 289–317. https://doi.org/10.1146/annurev.ne.19.030196.001445

Park, H., & Poo, M. M. (2013). Neurotrophin regulation of neural circuit development and function. Nature reviews. Neuroscience, 14(1), 7–23. https://doi.org/10.1038/nrn3379

Wayne, D.C. (2004). Neuroplasticity in mood disorders. Dialogues in clinical neuroscience. Neuroplasticity, 6, 199–216.

Binder, D. K., & Scharfman, H. E. (2004). Brain-derived neurotrophic factor. Growth Factors, 9, 123‒131.

Sarchielli, P., Greco, L., Stipa, A., Floridi, A., & V. Gallai (2002). Brain-derived neurotrophic factor in pa-tients with multiple sclerosis. J Neuroimmunol, 132(1-2), 180‒188.

Sarchielli, P., Zaffaroni, M., Floridi, A., Greco, L., Candeliere, A., Mattioni, A., Tenaglia, S., Di Filippo, M., & Calabresi, P. (2007). Production of brain-derived neurotrophic factor by mononuclear cells of patients with mul-tiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Multiple sclerosis (Houndmills, Basingstoke, England), 13(3), 313–331. https://doi.org/10.1177/1352458506070146

Azoulay, D. (2005). Short communication Lower brain-derived neurotrophic factor in serum of relapsing remit-ting. Journal of Neuroimmunology, 167, 215–218.

Yoshimura, S., Ochi, H., Isobe, N., Matsushita, T., Motomura, K., Matsuoka, T., … & Kira, J. (2010). Al-tered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 16(10), 1178–1188. https://doi.org/10.1177/1352458510375706

"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.